ADC Therapeutics to Report Second Quarter 2020 Financial Results on

ADC Therapeutics to Report Second Quarter

Financial Results on August 18, 2020

Lausanne, Switzerland, August

12, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering

the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological

malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020

at 8:30 am EDT to report financial results for the second quarter ended June 30, 2020 and provide business updates.

To access the call, please dial

646-787-0157 (domestic) or +41-22-5017540 (international)

and insert pin number 773478. A live webcast of the presentation will be available under "Events

and Presentations" on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com.

The archived webcast will be available after the completion of the event and for 30 days following the call.

About ADC Therapeutics

SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization

of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The

Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD)

technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and

substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline

of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical

trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in

tesirine (Lonca, formerly ADCT-402), the Company's lead product candidate, has been evaluated in a 145-patient pivotal Phase

2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% interim

overall response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the

Company's second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment

of relapsed or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The

Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For

more information, please visit https://adctherapeutics.com/ and follow the Company

on Twitter and LinkedIn.

Tel.: +1 917 288 7023

Tel: +41 (0) 43 268 3231

Tel.: +1 973-415-8838